Carbapenem-resistant Enterobacteriaceae (CRE) poses a significant threat to patients and healthcare systems in all EU/EEA countries. CRE infections are associated with high mortality, primarily due to delays in the administration of effective treatment and the limited availability of treatment options. New antibiotics capable of replacing carbapenems for their main indications are not likely to become available in the near future. CRE are adapted to spread in healthcare settings as well as in the community, and measures should address both routes of transmission.
This update of the 2016 ECDC rapid risk assessment on CRE evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Source: ECDC, 7 June 2018